7.18 (-%)
As of Nov 20, 2024
Source:
We are a clinical stage gene editing company dedicated to improving life by developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of our wholly owned proprietary ARCUS genome editing platform. The foundation of ARCUS is a natural homing endonuclease which allows us to replicate precise gene editing as it evolved in nature.
| Country | United States |
| Headquarters | durham, north carolina |
| Phone Number | 919-314-5512 |
| Industry | manufacturing |
| CEO | Michael Amoroso |
| Website | www.precisionbiosciences.com |